Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Modena, Alessandra, Ciccarese, Chiara, Iacovelli, Roberto, Brunelli, Matteo, Montironi, Rodolfo, Fiorentino, Michelangelo, Tortora, Giampaolo, Massari, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943092/
https://www.ncbi.nlm.nih.gov/pubmed/27471580
http://dx.doi.org/10.4081/oncol.2016.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943092/
https://www.ncbi.nlm.nih.gov/pubmed/27471580
http://dx.doi.org/10.4081/oncol.2016.293

Ejemplares similares